Jefferies Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $9
Buy Rating on ATyr Pharma Anchored by Upcoming Clinical Trials and Strong Financials
ATyr Pharma Price Target Maintained With a $16.00/Share by RBC Capital
ATyr Pharma Analyst Ratings
RBC Capital Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $16
RBC Capital Reaffirms Their Buy Rating on ATyr Pharma (ATYR)
Strong Buy Rating for ATyr Pharma Amid Clinical Progress and Financial Stability
ATyr Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
ATyr Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
RBC Capital Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $16
Buy Rating Affirmed: ATyr Pharma's Positive Clinical Developments and Strategic Expansion
ATyr Pharma Buy Rating: Novel Treatment's Market Potential and Financial Upside
aTyr Pharma Inc.: Jonestrading assumes coverage is a buy rating; target price is $22
ATyr Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
ATyr Pharma Analyst Ratings
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
No Data